Strategy and Planning

The biggest risk for pre-commercial companies is being singularly focused on a lean development program without planning for the additional data needed to support favorable pricing, clinical practice, and long-term market success. Early investment in medical affairs expertise is essential. Even a single FTE or experienced medical affairs consultant pays significant dividends later.

The first edition of "Connecting the Dots" was published on September 29, 2017. Since Sue Nemetz penned that inaugural piece, 12 authors from our team have contributed their insight, experience, and perspective on the biopharma industry.

Biopharma companies need to balance many critical priorities, especially those that are pre-commercial.

As summer winds down and vacations (sadly) come to an end, it’s a natural time to shift focus toward the close of the calendar year. Business leaders should prepare their organizations for a landscape that will be shaped by rapid technological changes, evolving market demands, and increasing global challenges.

Attending a large conference, medical congress, or trade show can be both exhausting and exhilarating. The decision to go in the first place depends on one’s goals, the expected ROI, and perspectives on who else might be attending.

Three notable transitions worthy of reflection at this point in time.

The energy was palpable at the 2025 Medical Affairs Professional Society (MAPS) Global Annual Meeting. Conversations were expansive, workshops immersive, and the questions being asked were less about what Medical Affairs can do and more about how it must evolve to meet the future.

In our biopharma world, we frequently hear the term “Key Business Questions (KBQs).” And while it’s often thrown around as a buzzword (or buzz phrase, in this case), it has quite a bit of practical value when its full depth is explored.

The value of New Product Planning (NPP) is often overlooked, but it plays a crucial role in the success of drug development projects. By incorporating NPP early in the process, you can increase the likelihood of commercial success and minimize risks.